All News

Patients with locally advanced penile squamous cell carcinoma who responded to neoadjuvant chemotherapy followed by consolidative lymphadenectomy experienced improved long-term survival outcomes.

The first patient has been enrolled in a clinical trial evaluating a reduced dose of post-transplant immunosuppressive chemotherapy cyclophosphamide for patients with blood cancers.

Mental health after cancer treatment has not been talked about enough, experts say, so how should survivors effectively care for their minds?

Accepting the unknown and understanding why random things happen helps me be hopeful as my daughter reached five years of cancer survivorship.

Orca-T outperformed post-transplant cyclophosphamide when it came to relapse-free survival and overall survival in patients with blood cancer who underwent a stem cell transplantation from a matched unrelated donor.

February brought in multiple FDA approvals in the oncology space. Here’s an overview of some of the most recent ones.

Researchers on a phase 1/2 trial provided the first dose of gotistobart plus Pluvicto to a specific patient population with prostate cancer.

Patients who were obese tended to have an increased risk of moderate to severe GVHD after undergoing allogeneic hematopoietic cell transplantation, research showed.

After I was diagnosed with colon cancer, I learned to take care of myself more and be more outspoken than ever before.

Treatment with rusfertide led to a decrease in the need for blood draws and decreased levels of red blood cells in patients with polycythemia vera.

Most patients with relapsed or refractory multiple myeloma responded to treatment with the CAR-T cell therapy, Carvykti, according to a small study.

My birthday makes me wonder about growing old — something I want to earn.

From Ben Lanzarone of “Happy Days” and “Grease” dying of lung cancer to “Good Morning America’s” Michael Strahan providing an update on his daughter’s medulloblastoma treatment, here’s what’s happening in the oncology space this week.

Prescribing newly FDA-approved drugs may take a long time before patients can start taking them, so experts told CURE® why.

While posttransplant Xospata did not worsen quality of life in patients with acute myeloid leukemia, it is essential that patients tell their providers about any side effects that they experience, an expert said.

An oncology nurse discusses how virtual reality can be used to educate patients and decrease stress before treatment or while in palliative care.

Treatment with Amtagvi, a TIL therapy recently approved for advanced melanoma, includes a three-week hospital stay upfront, but may lead to years of monitoring without more treatment needed, an expert explained.

A recent experience has emphasized to me that we should live life to its fullest every single day.

“We've all been touched by breast cancer in some way. And we need everybody to be a part of this solution,” Kristen Dahlgren told CURE, regarding her decision to be a co-founder of the Cancer Vaccine Coalition.

The Food and Drug Administration is reviewing the novel drug, linvoseltamab, for the treatment of patients with pretreated, relapsed or refractory multiple myeloma.

Keytruda plus chemotherapy has been granted a priority review by the FDA to treat certain patients with endometrial cancer.

The Food and Drug Administration is reviewing Dato-DXd for potential approval to treat pretreated advanced nonsquamous non-small cell lung cancer.

Having all of these screenings for cancer terrifies me, even though they could be almost certainly nothing.

Dr. Murugesan Manoharan of Miami Cancer Institute and Baptist Health South Florida shares key questions patients who have received a diagnosis of bladder cancer should ask their care team.

The Food and Drug Administration has approved a reduced dosing frequency of Tecvayli for patients with relapsed or refractory multiple myeloma who have achieved and maintained a complete response or better for at least six months.

The Food and Drug Administration granted a priority review to Krazati plus Erbitux for KRAS G12C-mutant locally advanced or metastatic colorectal cancer.

Personalized cancer vaccines are on the horizon and could be available for some patient populations as soon as next year, one expert said.

It’s not just toughing out the side effects from cancer treatment.